Canandaigua National Trust Co of Florida Makes New Investment in Johnson & Johnson $JNJ

Canandaigua National Trust Co of Florida acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 3,496 shares of the company’s stock, valued at approximately $926,000.

A number of other institutional investors also recently bought and sold shares of the business. Outlook Capital Management LLC acquired a new position in Johnson & Johnson in the 2nd quarter valued at about $28,000. Matrix Trust Co grew its stake in shares of Johnson & Johnson by 56.2% in the 2nd quarter. Matrix Trust Co now owns 150 shares of the company’s stock valued at $38,000 after purchasing an additional 54 shares during the last quarter. Hyposwiss Advisors SA acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $42,000. Montgomery Financial Services LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $43,000. Finally, Polaris Financial Partners acquired a new stake in shares of Johnson & Johnson during the third quarter worth $56,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

JNJ traded up $3.47 during trading on Wednesday, reaching $258.25. 5,394,094 shares of the stock were exchanged, compared to its average volume of 7,981,786. Johnson & Johnson has a 1 year low of $184.66 and a 1 year high of $281.07. The company has a market capitalization of $622.35 billion, a price-to-earnings ratio of 29.92, a P/E/G ratio of 2.48 and a beta of 0.21. The business’s 50 day moving average price is $265.86 and its two-hundred day moving average price is $248.63. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion for the quarter, compared to analyst estimates of $25.06 billion. During the same period in the previous year, the firm earned $2.77 EPS. The business’s revenue for the quarter was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.54 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were given a $1.34 dividend. This represents a $5.36 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JNJ. TD Cowen lifted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a report on Monday, July 13th. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $272.00 to $282.00 and gave the stock an “overweight” rating in a report on Monday, August 3rd. Bank of America reaffirmed a “neutral” rating and issued a $278.00 price objective on shares of Johnson & Johnson in a report on Tuesday, September 29th. Stifel Nicolaus set a $260.00 target price on Johnson & Johnson in a research report on Wednesday, July 15th. Finally, Freedom Capital raised Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $276.22.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying further upside from recent trading levels. RBC Capital Markets has also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Pipeline progress: Johnson & Johnson reported that the Tecvayli-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results support potential expansion of the company’s oncology franchise. 2026 Cancer Treatment Advances
• Positive Sentiment: Two-year Phase 3 data for oral psoriasis treatment ICOTYDE showed sustained skin clearance and consistent safety through Week 112, potentially adding another growth product to the Innovative Medicines portfolio. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Recent quarterly results showed 6.6% revenue growth, adjusted EPS above consensus and increased 2026 guidance, reinforcing the view that J&J may be developing into more than a purely defensive healthcare stock. Johnson & Johnson Is Becoming a Growth Stock
• Neutral Sentiment: J&J’s 64-year record of dividend increases continues to attract income investors, although the stock’s valuation means investors are paying for part of that quality and expected growth.
• Negative Sentiment: Investors remain concerned about upcoming patent and biosimilar pressure, a slower MedTech recovery, and ongoing talc litigation. These issues could limit earnings growth and offset strength in Innovative Medicines. Johnson & Johnson Dividend and Risk Analysis

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total transaction of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.